Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read‐outs
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
There is cumulating evidence that in vitro 3D tumor models with increased physiological relevance can improve the predictive value of pre‐clinical research and ultimately contribute to achieve decisions earlier during the development of cancer‐targeted therapies. Due to the role of tumor microenvironment in the response of tumor cells to therapeutics, the incorporation of different elements of the tumor niche on cell model design is expected to contribute to the establishment of more predictive in vitro tumor models. This review is focused on the several challenges and adjustments that the field of oncology research is facing to translate these advanced tumor cells models to drug discovery, taking advantage of the progress on culture technologies, imaging platforms, high throughput and automated systems. The choice of 3D cell model, the experimental design, choice of read‐outs and interpretation of data obtained from 3D cell models are critical aspects when considering their implementation in drug discovery. In this review, we foresee some of these aspects and depict the potential directions of pre‐clinical oncology drug discovery towards improved prediction of drug efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“Recent efforts from several consortia [72, 73] have precisely elaborated on this, resulting in the characterization of over 1000 cell lines and nearly 150 anticancer agents, and the collected information is now available to the research community.”
BackgroundMatrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
Organogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931 · cited 1×
“Organoids are organ-like structures that mimic in vitro the functionality of the tissue of origin and are obtained by the differentiation of pluripotent stem cells or isolated organ progenitors [82, 83].”
BackgroundEdmondson, R., Broglie, J. J., Adcock, A. F., & Yang, L. (2014) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2014.573 · Cited by 2,515 · cited 2×
“Other 3D tumor models include matrix-embedded cells in which cells are incorporated within biologicallyderived substrates (following the pioneer work of Mina Bissel and the proposed 3D models in laminin-enriched gels [12, 32] or other polymeric-based materials as preformed spheroids or as single cells that eventually…”
BackgroundSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Recent efforts from several consortia [72, 73] have precisely elaborated on this, resulting in the characterization of over 1000 cell lines and nearly 150 anticancer agents, and the collected information is now available to the research community.”
BackgroundOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“Only patients exhibiting KRAS and BRAF wild type would profit from treatments with anti-EGFR therapies [121, 122] and interestingly, inhibition of EGFR was less effective in 3D cultures than 2D in KRAS-wild type cell lines, mimicking the response usually obtained in vivo.”
BackgroundOrganoids as an in vitro model of human development and disease
Fatehullah, A., Tan, S. H., & Barker, N. (2016) · Nature Cell Biology · doi:10.1038/ncb3312 · Cited by 1,508 · cited 2×
“Organoids are organ-like structures that mimic in vitro the functionality of the tissue of origin and are obtained by the differentiation of pluripotent stem cells or isolated organ progenitors [82, 83].”
BackgroundThree-dimensional culture models of normal and malignant breast epithelial cells
Lee, G. Y., Kenny, P. A., Lee, E. H., & Bissell, M. J. (2007) · Nature Methods · doi:10.1038/nmeth1015 · Cited by 1,336
Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy
Mehta, G., Hsiao, A. Y., Ingram, M., Luker, G. D., & Takayama, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.045 · Cited by 1,172
Zanoni, M., Piccinini, F., Arienti, C., Zamagni, A., Santi, S., Polico, R., Bevilacqua, A., & Tesei, A. (2016) · Scientific Reports · doi:10.1038/srep19103 · Cited by 1,144 · cited 3×
“These assays need to be thoroughly validated for a proper application in 3D tumor cell cultures, aiming to attain reproducibility [5, 53].”
BackgroundSpheroid culture as a tool for creating 3D complex tissues
Fennema, E., Rivron, N., Rouwkema, J., van Blitterswijk, C., & de Boer, J. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.12.003 · Cited by 1,054 · cited 1×
“Apart from analytical hurdles, HTS 3D imaging results in vast amounts of data that require a tailored infrastructure for processing and analysis [124].”
BackgroundThree-dimensional culture systems in cancer research: Focus on tumor spheroid model
Nath, S., & Devi, G. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.013 · Cited by 919 · cited 18×
“Technological developments in miniaturized culture methods, imaging platforms, chemical and biological probes and gene reporter read-outs will contribute to enhance the amenability of HTS and HCS systems [131].”
BackgroundMethodInfluentialMaschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830 · cited 1×
“Only patients exhibiting KRAS and BRAF wild type would profit from treatments with anti-EGFR therapies [121, 122] and interestingly, inhibition of EGFR was less effective in 3D cultures than 2D in KRAS-wild type cell lines, mimicking the response usually obtained in vivo.”
BackgroundGene expression perturbation in vitro—A growing case for three-dimensional (3D) culture systems
Birgersdotter, A., Sandberg, R., & Ernberg, I. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.06.009 · Cited by 591
Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling
Skardal, A., Shupe, T., & Atala, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.003 · Cited by 512 · cited 1×
“Several organ-on-a-chip systems have already been reviewed elsewhere [113], namely tissue equivalents with physiological functions similar to those occurring in vivo.”
Background3D cell culture systems modeling tumor growth determinants in cancer target discovery
Thoma, C. R., Zimmermann, M., Agarkova, I., Kelm, J. M., & Krek, W. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.03.001 · Cited by 478
Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing
Gong, X., Lin, C., Cheng, J., Su, J., Zhao, H., Liu, T., Wen, X., & Zhao, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130348 · Cited by 373
Bioprinting for cancer research
Knowlton, S., Onal, S., Yu, C. H., Zhao, J. J., & Tasoglu, S. (2015) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.06.007 · Cited by 361
Luca, A. C., Mersch, S., Deenen, R., Schmidt, S., Messner, I., Schäfer, K.-L., Baldus, S. E., Huckenbeck, W., Piekorz, R. P., Knoefel, W. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059689 · Cited by 341 · cited 1×
“[120], which demonstrated the alteration of expression of EGFR (epidermal growth factor receptor), phosphor-AKT and phosphor-MAPK in 3D cultures for a cohort of colon cancer cell lines.”
BackgroundXu, F., Celli, J., Rizvi, I., Moon, S., Hasan, T., & Demirci, U. (2011) · Biotechnology Journal · doi:10.1002/biot.201000340 · Cited by 337 · cited 1×
“Co-cultures of epithelial cells with fibroblasts are most commonly found in the literature [95] and can, in some cases, eliminate the need to establish cultures in basement membrane preparations such as Matrigel, as demonstrated by [96].”
Stock, K., Estrada, M. F., Vidic, S., Gjerde, K., Rudisch, A., Santo, V. E., Barbier, M., Blom, S., Arundkar, S. C., Selvam, I., et al. (2016) · Scientific Reports · doi:10.1038/srep28951 · Cited by 253 · cited 19×
“The PREDECT Consortium addressed the latter in detail by comparing and characterizing in vitro co-culture models of breast, prostate and lung carcinomas, set-up as 2D monolayers, spheroids in suspension, spheroids embedded in different substrates, under static or dynamic culture conditions [28].”
BackgroundMethodInfluentialSelf-citationKenny, H. A., Krausz, T., Yamada, S. D., & Lengyel, E. (2007) · International Journal of Cancer · doi:10.1002/ijc.22874 · Cited by 243 · cited 1×
“The relevance of combining stromal cells to in vitro tumor cultures to model heterotypic cell-cell interactions has long been recognized [26, 29], however, the implementation of standardized co-cultures that include different cell types remains challenging [30].”
BackgroundThree-Dimensional In Vitro Co-Culture Model of Breast Tumor using Magnetic Levitation
Jaganathan, H., Gage, J., Leonard, F., Srinivasan, S., Souza, G. R., Dave, B., & Godin, B. (2014) · Scientific Reports · doi:10.1038/srep06468 · Cited by 231
Microfluidics: A New Tool for Modeling Cancer–Immune Interactions
Boussommier-Calleja, A., Li, R., Chen, M. B., Wong, S. C., & Kamm, R. D. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.12.003 · Cited by 224 · cited 1×
“Therefore, these microfluidic models constitute ideal setups to test libraries of compounds and biological formulations [112].”
BackgroundPatra, B., Peng, C.-C., Liao, W.-H., Lee, C.-H., & Tung, Y.-C. (2016) · Scientific Reports · doi:10.1038/srep21061 · Cited by 215
Unger, C., Kramer, N., Walzl, A., Scherzer, M., Hengstschläger, M., & Dolznig, H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.015 · Cited by 158
Han, B., Qu, C., Park, K., Konieczny, S. F., & Korc, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.003 · Cited by 53 · cited 2×
“3 Dynamic cultures In order to address the limitations of in vitro static cell culture in providing the adequate mechanical stimuli and mass transport from and into 3D models, various new cancer cell cultures on bioreactor-based platforms have been developed [47, 62].”
BackgroundKenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos-Hoff, M. H., Petersen, O. W., et al. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.02.004 · Cited by 2
Cited by
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Surendran, V., Rutledge, D., Colmon, R., & Chandrasekaran, A. (2021) · Biofabrication · doi:10.1088/1758-5090/abe1cf · Cited by 99
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models
Cox, M. C., Mendes, R., Silva, F., Mendes, T. F., Zelaya-Lazo, A., Halwachs, K., Purkal, J. J., Isidro, I. A., Félix, A., Boghaert, E. R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97894-0 · Cited by 58
Self-citation
Metadata
- Authors
- Santo, V. E., Rebelo, S. P., Estrada, M. F., Alves, P. M., Boghaert, E., & Brito, C.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2016-12-14
- Volume
- 12
- Issue
- 1
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2564990968
- Cited by
- 103
- References
- 31
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.